Drugmakers move for judgment against Humana's US generic drug case
( April 17, 2026, 22:31 GMT | Official Statement) -- MLex Summary: Taro Pharmaceuticals, West-Ward Pharmaceuticals, and other drugmakers moved for a summary judgment against Humana’s US antitrust claims over various generic drugs. They said that is undisputed that Humana’s damages expert calculated the volume of commerce for Humana’s indirect purchaser claims without making any attempt to exclude or net out any of the amounts paid by the federal government on Medicare Part D claims for drugs at Issue. “Because any overcharges on amounts paid by the government do not constitute 'actual damages' sustained by Humana, it was Humana’s burden to exclude the government’s Medicare Part D payments for the drugs at issue from its calculation of indirect VOC,” they argued.See attached files. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.